The inaugural ESMO Targeted Anticancer Therapies (TAT) Asia Congress 2025 will convene a diverse group of stakeholders to foster collaboration and accelerate the development of innovative cancer therapies. The congress aims to become a catalyst for global collaboration and innovation in oncology.
NRG Oncology has appointed Tambre Leighn as Chair of the Patient Advocate Committee and Chris Holsinger as Surgical Vice Chair of the Head and Neck Cancer Committee. These new leaders will focus on advancing patient advocate engagement and expanding NRG's head and neck cancer portfolio.
The American Society for Radiation Oncology (ASTRO) has updated its guideline on radiation therapy for high-grade diffuse gliomas, the most common primary brain tumor in adults. The new guideline provides evidence-based recommendations for multidisciplinary treatment and addresses optimal radiation dosing, fractionation, and techniques.
A new precision oncology paper presents a case of a 62-year-old man with metastatic colorectal cancer who underwent multiple lines of therapy. The WIN International Molecular Tumor Board proposed personalized treatment plans based on the tumor's unique genetic mutations, highlighting the growing role of precision oncology in guiding th...
Researchers discovered a new tumor-suppressive response targeting RNA Polymerase 1, inhibiting cancer cell growth and enhancing responsiveness to immunotherapies. The Pol 1 inhibitor BOB-42 reduced tumor growth by up to 77% in melanoma and colorectal cancers.
ASTRO welcomes Karen Davis as its first Vice President of Business Development and Marketing, leading the organization's business growth strategy. Davis will focus on public- and private-sector partnerships to advance ASTRO's mission and broaden its impact on cancer care.
Experts from the National Comprehensive Cancer Network (NCCN) and African Cancer Coalition gathered in Nairobi, Kenya to update NCCN Clinical Practice Guidelines in Oncology for Sub-Saharan Africa. The meeting aimed to improve cancer care in the region by sharing evidence-based recommendations.
The Dresden research team developed an autonomous AI agent for precision medicine that can process multimodal data and have reasoning capabilities. The AI agent reached correct clinical conclusions in 91% of cases and accurately cited relevant oncology guidelines in over 75% of its responses.
A recent study published in JAMA Oncology suggests that modern phase 3 oncology trials often prioritize overall survival over quality of life, which may not accurately reflect patient needs. Future trial designs should focus on improving overall survival and quality-of-life outcomes to better represent patient experiences.
The ATOMIC trial demonstrates a statistically significant improvement in disease-free survival with the addition of atezolizumab to standard adjuvant FOLFOX chemotherapy. Patients treated with atezolizumab had a 50% lower risk of disease recurrence or death compared to those receiving chemotherapy alone.
A phase II clinical trial shows that combining immune checkpoint inhibition with avelumab and cetuximab significantly improves progression-free survival compared to avelumab alone for patients with advanced cutaneous squamous cell carcinoma. The combination also leads to a confirmed objective response rate of 27.6%.
Researchers from Mayo Clinic Comprehensive Cancer Center will present practice-changing studies on chemotherapy approaches, AI applications in oncology, and new therapies for breast and melanoma. The event will feature 59 abstracts highlighting advancements in cancer care.
A new algorithm standardizes care for children with sickle cell disease who present to the ED with a fever, reducing hospitalizations by 10% without increasing readmissions. The algorithm uses predefined risk factors to determine treatment, making it safer and more efficient.
Researchers examined baseline characteristics of adolescent and young adult (AYA) cancer survivors seen in oncology primary care clinic, finding high rates of comorbidities and cardiovascular disease. They also studied the overexpression of IRAK4 protein in acute myeloid leukemia (AML) cells, with potential implications for treatment.
Christopher Flowers is being recognized for his commitment to mentoring young oncology professionals. He has advanced the development of multiple new treatments and helped characterize disparities in outcomes among patients with lymphoma.
Tracy Crane has been appointed as the new Chair of the NRG CPC Committee, focusing on improving adherence to healthy lifestyle behaviors, while Mylin Torres joins as Vice-Chair, leading research on breast cancer and radiation-induced side effects. Both experts bring extensive experience in clinical trials and mentorship.
The study found key differences in tumor biology between non-Hispanic Black and non-Hispanic white veterans, but similar survival outcomes when both groups had equal access to care. The research highlights the importance of broadening access to genomic tools and prioritizing equity in cancer treatment.
The American Society for Radiation Oncology (ASTRO) will host its 67th Annual Meeting in San Francisco from September 27 to October 1, 2025. The meeting will feature over 2,500 research presentations and posters on advances in radiation oncology and non-cancer indications.
City of Hope experts will present new cancer treatment approaches, targeted therapies and lifestyle changes aimed at reducing cancer risk and improving survival. Highlights include discussions on biomarkers in kidney cancer, symptom science and palliative care.
The NCCN Policy Summit brought together experts to discuss ways to strengthen collaborative cancer care, from early detection to survivorship. Key findings include the need for better communication and coordination between primary care and oncology providers.
Kristin Higgins has been appointed Chair of the NRG Lung Cancer Committee, succeeding Dr. Jeff Bradley, while Karthik Sundaram joins as Chair of the NRG Imaging Committee, succeeding Dr. Daniel Pryma. These appointments aim to advance research and clinical trials in these areas.
A new review advocates for building confidence in AI applications by implementing robust data governance frameworks, enhancing transparency, and involving stakeholders. The authors emphasize the importance of addressing ethical implications and ensuring equitable access to AI-driven innovations in clinical oncology.
NGR Oncology has created a new Sarcoma Subcommittee to improve outcomes for adults with cancer, focusing on building a robust program, collaborating with the Children's Oncology Group, and promoting sarcoma research. The subcommittee is led by Chair Dian Wang, MD, PhD, and Vice-Chairs William Tseng, MD, and Brian A Van Tine, MD, PhD.
At the 2025 Oncology Nursing Society Congress, Dana-Farber nurse scientists and clinicians presented key studies on hypersensitivity reaction simulation, bispecific antibody therapy, primary nursing, and non-pharmacologic interventions for anxiety and pain reduction. These research initiatives aim to enhance patient care, education, an...
The National Comprehensive Cancer Network (NCCN) has awarded four early-career oncologists with $150,000 in funding to tackle pressing challenges in cancer care. The recipients will support studies aiming to improve cancer outcomes through molecular residual disease-guided adjuvant therapy and electronic symptom monitoring.
The new Keck Medicine of USC – Newport Beach Radiation Oncology and Imaging Center offers biology-guided radiation therapy, using up-to-the-minute signals to track and treat cancer cells in real time. The center is equipped with state-of-the-art technology and will be the first in Orange County to provide this treatment option.
Jeffrey E. Lee, M.D. has been appointed Chief Medical Executive at MD Anderson, succeeding Dr. Peter WT Pisters. With over 34 years of tenure, Lee will lead the institution's efforts in research, patient care, prevention, and education. He brings a strong track record of leadership and clinical expertise to the role.
The collaboration aims to enhance clinical trial efficiency, reducing data entry time by up to 37 seconds per CRF. This enables researchers to focus more on patient care, improving the overall experience.
The NRG Oncology GOG-0263 phase III clinical trial found that adding cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy did not improve outcomes and led to increased toxicity. Radiotherapy alone remains the standard of care for early-stage, intermediate-risk cervical cancer.
The F. W. Bert and Mae Dean Wheeler Nurse Leadership Academy at MD Anderson aims to cultivate oncology nurse leaders through coaching, mentoring, and continuous learning opportunities. The academy will focus on empowering nurses to reach their personal and professional goals, driving industry change and improving healthcare systems.
The American Society for Radiation Oncology (ASTRO) has published its first clinical guideline on radiation therapy for anal cancer, providing guidance on treatment options and techniques. The guideline recommends a combination of radiation therapy and drug therapy as the standard of care, with intensity-modulated radiation therapy (IM...
Kimberly Stegmaier appointed as Chair of Pediatric Oncology at Dana-Farber Cancer Institute and Associate Chief of Division of Hematology/Oncology at Boston Children's Hospital. She will focus on acute leukemias and pediatric solid tumors, pioneering genomic approaches to identify new therapies for childhood cancer.
Dr. Gordon was named a Fellow of the American Society of Clinical Oncology (FASCO) in recognition of his extraordinary dedication to improving cancer research and patient outcomes. He has led HonorHealth Research Institute's clinical trials programs and contributed significantly to developing new cancer treatments.
The ACC Advancing the Cardiovascular Care of the Oncology Patient conference will provide clinicians with tools to improve cardiovascular care of cancer patients. Key sessions will include discussions on pulmonary tumor thrombotic microangiopathy, AI and technology in cardio-oncology.
The Neuro-Oncology Translational Research Training Program aims to bridge laboratory discoveries and clinical applications in neuro-oncology, targeting glioblastoma and brain metastases. The program provides predoctoral and postdoctoral trainees with cutting-edge lab experience and mentorship across multiple disciplines.
A new study published in Neuro-Oncology found that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously thought. The study suggests that doctors may need to rethink current screening guidelines for detecting brain metastasis in patients without symptoms.
Jeremy L. Davis, MD, has been appointed as the new Surgical Oncology Lead for UMGCCC and Chief of the Division of Surgical Oncology in the Department of Surgery at UMSOM. Dr. Davis is a nationally recognized surgical oncologist with expertise in gastric cancer research.
The Fourth Transatlantic Exchange in Oncology Conference will focus on Radiopharmaceutical Therapy Meets Oncology, with key presentations on precision oncology and radioligand therapies. The meeting aims to facilitate the exchange of information and talents toward one goal: curing cancer.
NRG Oncology has established a new Theranostics Subcommittee to develop a more robust theranostics program within its portfolio. The subcommittee will serve as a resource for research investigators and collaborate with other organizations to enhance the effects of treatment on targeted cancer.
A Phase III clinical trial found that stereotactic body radiotherapy (SBRT) added to sorafenib improved progression-free survival and overall survival in patients with locally advanced hepatocellular carcinoma, particularly those with macrovascular invasion. The study also showed improvements in quality of life for these patients.
The European Society of Cardiology emphasizes the importance of including heart and cardiovascular health in cancer treatment plans. Recent studies estimate that approximately one-third of patients experience mild toxicities, while 3% develop moderate toxicity. The ESC is launching a new conference to address this growing epidemic.
Researchers analyzed data from 11,797 adults with advanced solid cancers and found no difference in mortality rates during the shortage period. Prescription rates for cisplatin and carboplatin fell less than three percent overall, with alternative therapies helping mitigate the crisis.
A team of UNC-Chapel Hill researchers will develop an oncology health learning system using AI-ready data to generate real-time identification of new cancer cases and support personalized treatments. The project aims to improve cancer diagnosis, care equity, and quality by creating accessible tools for health providers.
The ESMO Immuno-Oncology Congress 2024 will present key findings on new therapeutic opportunities and management of treatment-related toxicities. Leading experts will share their research advancements in the rapidly evolving field of immuno-oncology.
The Gustave Roussy Prize recognizes scientists whose work improves cancer treatment and patient outcomes. Established by Pierre Fabre Laboratories, the €200,000 award aims to push boundaries of oncology and offer personalized treatments.
The National Comprehensive Cancer Network (NCCN) is collaborating with leading cancer centers in China to improve cancer treatment and outcomes. NCCN Guidelines provide evidence-based recommendations for cancer treatment, prevention, and supportive care, guiding high-quality care globally.
Neuro-oncology experts developed guidelines to standardize AI use in brain cancer diagnosis and treatment. The recommendations aim to ensure reliable clinical trial results and protect patients.
Tiffany Richards, a seasoned oncology nurse supervisor, receives the prestigious award for her exceptional patient care and dedication to clinical excellence. She joins an elite group of nursing professionals who have made significant contributions to advancing cancer treatment.
A randomized trial halted after patients in the control arm reached a record high two-year progression-free survival rate of 98%. Deintensified treatments involving lower radiation dose and immunotherapy did not perform as well as standard chemoradiation.
The NRG Oncology trial found that atezolizumab given concurrently with chemoradiation did not improve overall survival for patients with limited-stage small cell lung cancer. However, the study suggests that LS-SCLC patients benefit from immunotherapy when given after completion of chemoradiation.
UCLA investigators presented data on chemoradiotherapy in rectal cancer, MRI-guided radiotherapy for prostate cancer, and symptom self-reporting during treatment. Researchers developed a predictive model to identify patients most likely to respond to chemoradiotherapy in rectal cancer.
Leading researchers from Penn Medicine will showcase clinical trial results and new data on FLASH radiation therapy. The institution is one of the world’s leading academic medical centers, with a proud history of groundbreaking discoveries and innovations.
The Cancer Cooperative Group System is being re-engineered to bring new money to correlative science research through public-private partnerships, aiming to remove barriers for researchers to access biological samples. This will facilitate the integration of innovative science into cancer clinical trials.
A new study from NRG Oncology found that whole-breast irradiation (WBI) was not statistically equivalent to accelerated partial-breast irradiation (APBI) in local tumor control. The QOL sub-study also showed that APBI may be preferred by some patients due to reduced fatigue and extended treatment time.
SourceNRG Oncology·JournalJNCI Journal of the National Cancer Institute·TypeRandomized controlled/clinical trial·DateSep 16, 2024
A new study published in Annals of Oncology found that long-course radiotherapy is safer and more effective than short-course radiotherapy for preserving organs in rectal cancer patients. The treatment was shown to prevent regrowth of the primary tumour, but had similar overall survival rates.
Researchers found that adding metastasis-directed radiation therapy to standard chemotherapy improved progression-free survival by 7.8 months in patients with oligometastatic pancreatic cancer. The approach also showed increased immune responses and longer survival times.
A year-long pilot program found that external mentorship increased confidence, furthered career development, and facilitated networking opportunities for trainees in classical hematology. The program paired hematology/oncology fellows with mentors outside their institutions to meet virtually each month.
A new AI protocol called DeepHRD enables accurate, instantaneous detection of cancer genomic biomarkers directly from tumor biopsy slides. This breakthrough technology saves weeks and thousands of dollars from clinical oncology treatment workflows, providing access and equity in cancer care for resource-constrained settings.
A new study found that two Medicaid policies can interact to increase oncology clinical trial enrollment among Black and Hispanic patients. Medicaid expansion under the ACA alone did not improve diversity, but states with pre-existing mandates requiring coverage of clinical trial costs saw a significant increase.
New article outlines considerations for clinical trial design to enhance OS collection and analysis. Key findings include the importance of prespecified statistical analyses of OS as a safety endpoint and robust assessments to support approval.